par Hanquet, Germaine;Lernout, Tinne;Vergison, Anne 
;Verhaegen, Jan;Kissling, Esther;Tuerlinckx, David;Malfroot, Anne;Swennen, Béatrice ;Sabbe, Martine;Belgian IPD Scientific Committee,
Référence Vaccine, 29, 16, page (2856-2864)
Publication Publié, 2011-04
;Verhaegen, Jan;Kissling, Esther;Tuerlinckx, David;Malfroot, Anne;Swennen, Béatrice ;Sabbe, Martine;Belgian IPD Scientific Committee, Référence Vaccine, 29, 16, page (2856-2864)
Publication Publié, 2011-04
Article révisé par les pairs
| Résumé : | In Belgium, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the national schedule in 2007. The early impact of PCV7 vaccination on paediatric invasive disease was estimated by comparing pre- and post-vaccination incidence from national surveillance. In children <2 year-olds, vaccine-serotype incidence declined by 96% but non-vaccine-types increased 2-3-fold. Overall invasive disease decreased by 23-46%, depending on adjustment for under-reporting and pre-vaccine trends. Non-vaccine-types 1 and 19A had increased before PCV7 use, suggesting the contribution of other factors. Estimation of PCV7 impact comparing pre- and post-vaccination data should adjust for pre-vaccine trends, and serotype dynamics need further exploration. |
